Information That Can Help Define Treatment Options and Make Treatment Decisions for Breast and Colon Cancer Patients
About the Oncotype DX Breast Cancer Assay and Early Stage Breast Cancer
The Oncotype DX breast cancer assay, is a test that examines a breast cancer patient´s tumor tissue at a molecular level, and gives information about her individual disease. This information can help individualize breast cancer treatment planning and identify options. The Oncotype DX breast cancer test is the only multigene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. The Oncotype DX gene expression assay is intended to be used by women with early-stage (stage I or II), node-negative, estrogen receptor-positive (ER+) invasive breast cancer who will be treated with hormone therapy.
Oncotype DX Breast Cancer Assay Evaluation and Impacts on Breast Cancer Treatment Options
The Oncotype DX breast cancer multigene expression assay has been extensively evaluated in 14 clinical studies involving more than 4,000 breast cancer patients worldwide, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology.
Both the American Society of Clinical Oncology and the National Comprehensive Cancer Network recommend the use of Oncotype DX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. For complete information on Oncotype DX for Patients & Caregivers, Healthcare Providers, and Managed Care Organizations, visit OncotypeDX.com.
For additional information for Patients & Caregivers and detail about breast cancer treatment options, visit MyTreatmentDecision.com.
About the Oncotype DX Colon Cancer Assay and Stage II Colon Cancer
The Oncotype DX colon cancer assay is a colon cancer test that provides an individual, numerical assessment of how likely colon cancer is to return in patients with stage II colon cancer following surgery to remove the tumor. The multigene expression assay examines the activity of 12 genes within a patient´s tumor sample in order to provide individualized information to each person and their physician about the specific biological make-up of their colon cancer.
The Oncotype DX assay is appropriate for people who are newly diagnosed with stage II colon cancer and is performed on tumor tissue removed during the original surgery. Because of this, the Oncotype DX assay does not require any additional surgery or procedures in order for a patient to get the test.
For detailed information about the Oncotype DX breast cancer assay, please call: (866) ONCOTYPE or visit www.oncotypedx.com.
Watch videos about the gene expression assay online.
Patient Stories provide detailed information about patients' experiences with Oncotype DX assays.
Learn more about Genomic Health’s products in development: